Trick or Trade- Prohost Biotech - Exclusive Biotech Research

Category: Trick or Trade

Promising Stocks in the First Two Trading Days of 2023

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, o n Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stocks plummeted,...

January 4, 2023

Stocks Outperforming Today

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata Pharmaceuticals ( RETA ) bluebird bio Inc ( BLUE ) And Vertex Pharmaceuticals ( VRTX ) ...

January 5, 2023

It’s All About Common Sense: Intellia Therapeutics

The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a development-stage firm such as CRiSPR gene editing IntelliaTherapeutics ( NTLA ) when only based on stopping short of attaining analysts’ expectations with regard to...

March 9, 2021

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. FDA is reviewing Travere Therapeutics’ ( TVTX ) New Drug Application ( NDA ) under Subpart H for accelerated approval of sparsentan for IgA...

February 2, 2023

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

Xenon Pharmaceuticals Xenon Pharmaceuticals ( XENE ) - a clinical stage biopharmaceutical company developing novel treatments aimed at improving the lives of patients with neurological disorders. The firm is advancing its neurology pipeline to address diseases with unmet medical need. The...

February 7, 2023

Endogena Therapeutics: Treating Retinitis Pigmentosa and Other Devastating Degenerative Diseases

Endogena Therapeutics The US FDA designated Fast Track development program for the investigation of Endogena Therapeutics' product EA-2353 for the treatment of Retinitis Pigmentosa ( RP ). The Fast Track is a process designed to enable patients to benefit earlier...

February 8, 2023

Why the Current Interest in Ventyx Biosciences

The Current Interest in Ventyx Biosciences Answered 1. Ventyx Biosciences Focus We like the fact that Ventyx Biosciences ( VTYX ) is not just focusing on developing innovative oral Drugs for people living with autoimmune and inflammatory disorders, but also...

March 7, 2023

Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

Kite Pharma - A Gilead Company In The NEWS Gilead Sciences' ( GILD ) firm Kite Pharma, announced that the European Commission ( EC ) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory...

June 29, 2022

Acquired by Merck or Not, Seagen Will, Sooner or Later, Outperform

Is Merck to Acquire Seagen? The Wall Street Journal reported that Merck is in advanced talks to buy Seagen in a deal that could be worth $40 billion or more. The report, cited by people familiar with the matter, said...

July 8, 2022

Why Rhythm Pharmaceuticals Stock Price is Rebounding

Rhythm Pharmaceuticals is Rebounding Rhythm Pharmaceuticals ( RYTM ) announced yesterday, July 20, 2022, that the French National Agency for Medicines and Health Products Safety ( ANSM ) and Haute Autorité de santé ( HAS ) have granted pre-marketing authorization...

July 21, 2022

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024